Search Results - "Dreazen, O."

The past and present role of the Sabin-Feldman dye test in the serodiagnosis of toxoplasmosis by REITER-OWONA, I, PETERSEN, E, HAYDE, M, HOLLIMAN, R, HO-YEN, D. O, JANITSCHKE, K, JENUM, P. A, NASER, K, OLSZEWSKI, M, THULLIEZ, P, SEITZ, H. M, JOYNSON, D, ASPÖCK, H, DARDE, M. L, DISKO, R, DREAZEN, O, DUMON, H, GRILLO, R, GROSS, U

“…The dye test for the detection of Toxoplasma-specific antibodies was first described by Sabin and Feldman 50 years ago. The test is highly specific and…”
Get full text

A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia by Fainstein, E, Marcelle, C, Rosner, A, Canaani, E, Gale, R. P, Dreazen, O, Smith, S. D, Croce, C. M

“…The leukaemic cells of more than 90% of chronic myelogenous leukaemia (CML) patients and of 10% of acute lymphocytic leukaemia (ALL) patients carry the t(9:22)…”
Get full text

Activation of the c-mos Oncogene in a Mouse Plasmacytoma by Insertion of an Endogenous Intracisternal A-Particle Genome by Canaani, E., Dreazen, O., Klar, A., Rechavi, G., Ram, D., Cohen, J. B., Givol, D.

“…The activation of the cellular oncogene c-mos in mouse plasmacytoma XRPC24 was found to result from the insertion of a 4.7-kilobase-pair cellular DNA element,…”
Get full text

bcr-abl RNA in Patients With Chronic Myelogenous Leukemia by Shtivelman, E., Gale, R.P., Dreazen, O., Berrebi, A., Zaizov, R., Kubonishi, I., Miyoshi, I., Canaani, E.

“…The major consequence of the formation of the Philadelphia (Ph1) chromosome characteristic of leukemia cells of patients with chronic myelogenous leukemia…”
Get full text

bcr-abl RNA in patients with chronic myelogenous leukemia by Shtivelman, E, Gale, RP, Dreazen, O, Berrebi, A, Zaizov, R, Kubonishi, I, Miyoshi, I, Canaani, E

“…The major consequence of the formation of the Philadelphia (Ph1) chromosome characteristic of leukemia cells of patients with chronic myelogenous leukemia…”
Get full text

Molecular Abnormalities of bcr and c-abl in Chronic Myelogenous Leukemia Associated With a Long Chronic Phase by Dreazen, Orna, Berman, Michael, Gale, Robert Peter

“…Median duration of the chronic phase of chronic myelogenous leukemia (CML) is 3 years; <20% of patients have a chronic phase >7 years. It is unknown whether…”
Get full text

Characterization of bcr gene products in hematopoietic cells by Li, W J, Dreazen, O, Kloetzer, W, Gale, R P, Arlinghaus, R B

“…The bcr gene plays a critical role in the pathogenesis of two human leukemias associated with the Philadelphia chromosome: chronic myelogenous leukemia (CML)…”
Get more information

CML-T1: A Cell Line Derived From T-Lymphocyte Acute Phase of Chronic Myelogenous Leukemia by Kuriyama, Kazutaka, Gale, Robert Peter, Tomonaga, Masao, Ikeda, Shuichi, Yao, Eiichi, Klisak, Ivana, Whelan, Kathy, Yakir, Hadas, Ichimaru, Michito, Sparkes, Robert S., Dreazen, Orna

“…Most data suggest that malignant transformation in chronic myelogenous leukemia (CML) occurs in hematopoietic stem cell that is the progenitor of myelopoiesis…”
Get full text

Accreditation of sampling activities by DREAZEN, Orna

“…Since the introduction of ISO/IEC 17025 it is a requirement for all accredited laboratories to include sampling in their quality statements. It is well…”
Get full text

B cell acute lymphoblastic leukemia (ALL) in donor cells following bone marrow transplantation for T cell ALL by Feig, S A, Dreazen, O, Simon, M, Wiley, F, Schreck, R, Gale, R P

“…Leukemia recurred in a child with acute lymphoblastic leukemia after a bone marrow transplant. The pre-transplant leukemia was of T cell origin whereas the…”
Get more information

Current best practice for traceability in testing laboratories, when certified reference materials are unavailable by ENGELHARD, Tina, DREAZEN, Orna

“…Since the implementation of ISO/IEC 17025 in 2002, all accredited laboratories (at the least) need to establish traceability in all their tests and calibration…”
Get full text

Proficiency testing as a tool for assessing the medical and economic impact of laboratory results: The blood coagulation case by DREAZEN, Orna, FELLER, Etty, LESHNO, Moshe

“…An international commercial proficiency testing scheme was used to evaluate the impact of laboratory results on clinical decisions. The affect on atrial…”
Get full text

Influence of buffer quality on pH measurement uncertainty: prediction and experimental evaluation by Ekeltchik, Irina, Kardash-Strochkova, Elena, Dreazen, Orna, Kuselman, I.

“…Dependence of the uncertainty of a pH measurement result on the quality of buffers (i.e. the uncertainty of their certified pH values) at different levels of…”
Get full text

Do oncogenes determine clinical features in chronic myeloid leukaemia? by Dreazen, O, Klisak, I, Rassool, F, Goldman, J M, Sparkes, R S, Gale, R P

“…Oncogene abnormalities are thought to have a central role in some human malignant disorders, particularly Burkitt leukaemia/lymphoma and chronic myeloid…”
Get more information

Molecular biology of chronic myelogenous leukemia by Dreazen, O, Canaani, E, Gale, R P

“…In this review we have described molecular consequences of the t(9;22) translocation typical of CML and some cases of ALL. This data indicates an important…”
Get more information

Molecular abnormalities of bcr and c-abl in chronic myelogenous leukemia associated with a long chronic phase by Dreazen, O, Berman, M, Gale, RP

“…Median duration of the chronic phase of chronic myelogenous leukemia (CML) is 3 years; less than 20% of patients have a chronic phase greater than 7 years. It…”
Get full text

Multiple molecular abnormalities in Ph1 chromosome positive acute lymphoblastic leukaemia by Dreazen, O, Klisak, I, Jones, G, Ho, W G, Sparkes, R S, Gale, R P

“…The Ph1 chromosome is present in 95% of patients with chronic myelogenous leukaemia (CML). The Ph1 chromosome also occurs in 5-25% of children and adults with…”
Get more information

The bcr gene is joined to c-abl in Ph1 chromosome negative chronic myelogenous leukemia by Dreazen, O, Klisak, I, Rassool, F, Goldman, J M, Sparkes, R S, Gale, R P

“…The relationship between chronic myelogenous leukemia (CML) with and without the Ph1 chromosome is controversial. Although some suggest that these disorders…”
Get more information

A Ph1 chromosome positive B cell line expresses the fusion protein P 210 by Munker, R, Miller, C W, Berenson, J, Dreazen, O, Koeffler, H P

“…We established a B lymphocyte line from bone marrow cultures of a patient with Philadelphia chromosome (Ph1) positive chronic myelogenous leukemia. The cell…”
Get more information

The genomic breakpoint in a patient with Philadelphia-positive acute leukemia is 5' of the breakpoint cluster region by Rassool, F, Foroni, L, Rahemtulla, A, Dreazen, O, Wiedemann, L, Guo, A P, Legon, S, Catovsky, D, Luzzatto, L, Goldman, J

“…We report a case of acute leukemia in which studies at presentation showed both myeloid and lymphoid cell surface markers. At relapse membrane markers studies…”
Get more information